

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated 8 September 2016 (the “**Prospectus**”) of Jacobson Pharma Corporation Limited (the “**Company**”) for detailed information about the Global Offering before deciding whether or not to invest in the Offer Shares.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer for sale or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. There will be no public offer of securities of the Company in the United States.*

Jacobson Pharma Corporation Limited

雅各臣科研製藥有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

ANNOUNCEMENT

Unless otherwise defined in this announcement, capitalized terms used in this announcement shall have the same respective meanings as defined in the Prospectus.

Regarding recent media coverage on the Company’s Hong Kong Public Offering as well as the Prospectus mentioning the name of the Hospital Authority (“Hospital Authority”) and the business relationship between the Company and the Hospital Authority, the Company wishes to clarify that the disclosure and release of such information therein are compiled and prepared by the Company without any review or endorsement by the Hospital Authority. The Hospital Authority hence shall assume no responsibility as to the accuracy and completeness of the relevant information disclosed therein.

The Company hereby expresses its most sincere apologies for the inconvenience caused to Hospital Authority.

The Directors are of the view that all material information relevant to the Group has been disclosed in the Prospectus, and such information remain accurate and complete. The Company confirms that since the date of the Prospectus, there has been no significant change affecting any matter contained in the Prospectus and that no significant new matter has arisen which would warrant the issuance of a supplemental prospectus under Rule 11.13 of the Listing Rules.

On behalf of the board of the Company
Wong Wai Ming
Company Secretary

Hong Kong, 15 September 2016

As at the date of this announcement, the executive Directors of the Company are Mr. Sum Kwong Yip, Derek, Mr. Yim Chun Leung and Mr. Lo Chun Bun; the non-executive Director is Professor Lam Sing Kwong, Simon; and the independent non-executive Directors are Professor Chow Hee Lum, Albert, Dr. Lam Kwing Tong, Alan and Mr. Young Chun Man, Kenneth.